Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Stressed tumor cell, chemosensitized cancer

Nature Medicine volume 17, pages 1552–1554 (2011)Cite this article

Subjects

miR-200 family expression results in highly proliferative ovarian cancer cells. Yet this expression is also linked to longer overall survival in women with ovarian cancer. A new study sheds light into this apparent paradox showing that two members of this family—miR-141 and miR-200a—not only boost tumor growth but also sensitize tumor cells to chemotherapy (pages 1627–1635).

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: miR-200 miRNAs expression influences sensitivity to chemotherapeutic agents used in the treatment of ovarian cancer in various ways.

Marina Corral

References

  1. Iliopoulos, D. et al. Mol. Cell 39, 761–772 (2010).

    Article  CAS  Google Scholar 

  2. Gregory, P.A. et al. Nat. Cell Biol. 10, 593–601 (2008).

    Article  CAS  Google Scholar 

  3. Iorio, M.V. et al. Cancer Res. 67, 8699–8707 (2007).

    Article  CAS  Google Scholar 

  4. van Jaarsveld, M.T. et al. Int. J. Biochem. Cell Biol. 42, 1282–1290 (2010).

    Article  CAS  Google Scholar 

  5. Matsuzawa, A. & Ichijo, H. Biochim. Biophys. Acta 1780, 1325–1336 (2008).

    Article  CAS  Google Scholar 

  6. Nguyen, T., Nioi, P. & Pickett, C.B. J. Biol. Chem. 284, 13291–13295 (2009).

    Article  CAS  Google Scholar 

  7. Dolado, I. et al. Cancer Cell 11, 191–205 (2007).

    Article  CAS  Google Scholar 

  8. Mateescu, B. et al. Nat. Med. 17, 1627–1635 (2011).

    Article  CAS  Google Scholar 

  9. Issbrücker, K. et al. FASEB J. 17, 262–264 (2003).

    Article  Google Scholar 

  10. Hu, X. et al. Gynecol. Oncol. 114, 457–464 (2009).

    Article  CAS  Google Scholar 

  11. Marchini, S. et al. Lancet Oncol. 12, 273–285 (2011).

    Article  CAS  Google Scholar 

  12. Cochrane, D.R. et al. J. Oncol. 2010, 821717 (2010).

    Article  Google Scholar 

  13. Leskelä, S. et al. Endocr. Relat. Cancer 18, 85–95 (2011).

    Article  Google Scholar 

  14. Alexandre, J. et al. Cancer Res. 67, 3512–3517 (2007).

    Article  CAS  Google Scholar 

  15. Cho, J.M. et al. Cancer Lett. 260, 96–108 (2008).

    Article  CAS  Google Scholar 

  16. Helleman, J. et al. Gynecol. Oncol. 117, 170–176 (2010).

    Article  CAS  Google Scholar 

  17. Konstantinopoulos, P.A. et al. Cancer Res. 71, 5081–5089 (2011).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Erik A.C. Wiemer is at the Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.,

    Erik A C Wiemer

Authors
  1. Erik A C Wiemer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Erik A C Wiemer.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wiemer, E. Stressed tumor cell, chemosensitized cancer. Nat Med 17, 1552–1554 (2011). https://doi.org/10.1038/nm.2593

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.2593

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing